Health Ministry of Moldova Publishes Flu and ARVI Treatment Protocols
Flu and ARVI treatment protocols have been published on the official website of the Ministry of Health of the Republic of Moldova.
The original antiviral drug Kagocel, developed by the Russian company NIARMEDIC PLUS, is included in the National Clinical Protocol for the treatment of influenza and ARVI in children from 3 years of age. The document has been compiled by leading practitioners of the Republic.
The data of the large-scale non-interventional study of the drug Kagocel, completed in November 2016 within the framework of the international project "Treatment of ARVI and Influenza in Routine Clinical Practice (FLU-EE)", confirmed the effectiveness of Kagocel in the complex treatment of influenza and ARVI in patients of different ages with different severity levels, regardless of time of prescription, including late treatment. The study involved 18,946 patients from 262 medical centers (Russia, Moldova, Armenia and Georgia) with a proven diagnosis of SARS and influenza.
NEARMEDIC PLUS is a Russian pharmaceutical, biotechnological, and medical company, founded in 1989 by a group of scientists of N. F. Gamalei Scientific Research Institute of Epidemiology and Microbiology. Activities of the company include creation of new original medicines, their production and introduction into medical practice; development, production and sale of diagnostic test systems and medical products; complex delivery of laboratory equipment for medical laboratories; rendering medical and laboratory services to the population (through the NEARMEDIC chain of clinics). All these activities are aimed at improvement of health care in Russia.
Kagocel is an original antiviral drug developed by Russian scientists for the treatment and prevention of influenza and SARS in adults and children from 3 years of age. It is a non-prescription drug featuring high safety profile and a convenient regimen. The effectiveness of Kagocel is confirmed by registration clinical studies assessing the therapeutic efficacy and safety of the drug for adults and children from 3 years of age.
← Back to the list